Who Paid My Doc
Eman Alhussain
Endocrinology, Diabetes & Metabolism Fort Smith, AR Medical Doctor
NPI 1174121784 CMS profile 11947130
2713 S 74Th St Ste 204, Fort Smith, AR 72903
General payments
$259
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Eman Alhussain of Fort Smith, AR is reported in the CMS Open Payments database as having received $259 across 11 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 23rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $259 | 11 |
Beside peers
- Eman Alhussain
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Eman Alhussain were reported at $259. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Eman Alhussain | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $494 | $123–$2,253 | $163 |
| 2020 | $0 | $335 | $85–$1,841 | $114 |
| 2021 | $0 | $398 | $88–$1,981 | $132 |
| 2022 | $0 | $364 | $88–$1,568 | $149 |
| 2023 | $0 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $259 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
518
Drug cost
$250,748
Branded share of claims
55%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 94 | $115,150 | |
| Jardiance Empagliflozin | Brand | 45 | $38,303 | |
| Trulicity Dulaglutide | Brand | 36 | $36,593 | |
| Farxiga Dapagliflozin Propanediol | Brand | 37 | $28,503 | |
| Mounjaro Tirzepatide | Brand | 16 | $17,781 | |
| Januvia Sitagliptin Phosphate | Brand | 15 | $8,305 | |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | Brand | 15 | $1,829 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 13 | $1,457 | |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | Brand | 14 | $836 | |
| Levothyroxine Sodium | Generic | 66 | $729 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
11 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Arkansas
Richard Griffiths
Endocrinology, Diabetes & Metabolism · Little Rock, AR
Catherine Kilpatrick
Endocrinology, Diabetes & Metabolism · Fayetteville, AR
Adam Maass
Endocrinology, Diabetes & Metabolism · Springdale, AR
James Thrasher
Endocrinology, Diabetes & Metabolism · Little Rock, AR
Kevin Ganong
Endocrinology, Diabetes & Metabolism · Jonesboro, AR
Cory Gamble
Endocrinology, Diabetes & Metabolism · Fort Smith, AR
Related records
Endocrinology, Diabetes & Metabolism in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.